Research Paper Volume 16, Issue 2 pp 1581—1604
Identification of a basement membrane gene signature for predicting prognosis and estimating the tumor immune microenvironment in prostate cancer
Figure 8. Exploring the relationship between BMRS and TIME, immunotherapy and chemotherapy. (A) Comparison of stromal score, immune score and ESTIMATE score between the high-risk and low-risk groups. (B) Differences in tumor immune cell infiltration between the high-risk and low-risk groups. (C) TIDE scores between high-risk and low-risk groups. (D–I) Association between BMRS and IC50 of chemotherapeutic agents in PCa patients, including Vinblastine, Cisplatin, Docetaxel, Methotrexate, Etoposide and Gemcitabine. ns: p ≥ 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001. TIDE, Tumor Immune Dysfunction and Exclusion. ICIs, immune checkpoint inhibitors. TIME, tumor immune microenvironment.